China’s Looming Diabetes Epidemic
A study released last week found China has 114 million diabetics or 21.6 million more than the Brussels-based federation estimated in November. Extending average care to the enlarged population of diabetes sufferers would wipe out all of Chinas additional investment in health. The government budgeted spending 260.25 billion yuan ($42.5 billion) this year, a 27 percent increase, on basic medical services and subsidies for a state-run health insurance program. Chinas diabetes costs will balloon, with almost 500 million Chinese at risk of developing the disease.
For the original version including any supplementary images or video, visit http://www.bloomberg.com/news/2013-09-11/diabetes-ailing-114-million-chinese-risks-ravaging-health-budget.html
Discovery: Marker predicts diabetes 12 years before disease begins (Video)
The detection of 2-AAA is a simple test that can be done from a blood sample. The discovery was based on human sampling from the Framingham Heart Study that tracked potentially diabetic people and those that had no potential for diabetes for 12 years. The validity of 2-AAA as a biomarker for diabetes was confirmed in mouse studies that compared fasting plasma glucose levels in mice that ate a high fat diet with mice that ate a regular diet. 2-AAA administered to mice and humans increased insulin production. The researchers found no correlation with and no interference from any other known biomarkers for diabetes.
For the original version including any supplementary images or video, visit http://www.examiner.com/article/discovery-marker-predicts-diabetes-12-years-before-disease-begins
It is therefore imperative for the government to construct a diabetes prevention and control system that raises awareness of the disease, promotes healthier life styles, enables early identification of the disease and risk factors, and encourages timely and effective treatment and interventions. This post appears courtesy of CFR.org , an Atlantic partner site. Consumer habits have changed in surprising ways Video An animated guide to the different energy sources that power our nation Video Business editor Derek Thompson looks at how such a simple commodity became as pricey as soda. Video A quick, animated look at at where emissions come from on our planet Video A story of loss leaders, irrational consumers, and infinite mimosas Video Business editor Derek Thompson outlines potential threats on the horizon. Video A brief history of technological progress and why it’s not necessarily a bad thing Video An animated guide to how it turns into fuel for cars, jets, and more Video Inequality explained in pie charts (made of actual pie) Video An animated look at how far solar has come since it emerged in the 1950s Video Two longtime Atlantic writers hit the runway in their Cirrus plane. Video An animated look at why production has skyrocketed in recent years Video A quick explainer on monetary policy Video The Eurythmics star discusses insights from her life as a musician, AIDS activist, mother, and more.
For the original version including any supplementary images or video, visit http://www.theatlantic.com/china/archive/2013/09/chinas-looming-diabetes-epidemic/279670/
Cancer drug has potential to treat diabetes
The drug, aflibercept (marketed as Eylea or Zaltrap), is used to treat metastatic colorectal cancer and a form of macular degeneration. Aflibercept is a member of a family of proteins that inhibit the vascular endothelial growth factor, or VEGF, pathway. It works by blocking the growth of the blood vessels into tumors and starving them of oxygen. The lab of Calvin Kuo, MD, PhD, professor of medicine, identified a series of protein interactions that link VEGF inhibitors and blood glucose levels.
For the original version including any supplementary images or video, visit http://timesofindia.indiatimes.com/life-style/health-fitness/health/Cancer-drug-has-potential-to-treat-diabetes/articleshow/22629436.cms